Other Species / Isoforms
  SLK (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsFFNFRKI
0 6
SLK (human) ______MsFFNFRKI S2-p
SLK iso2 (human) ______MSFFNFRKI S2
SLK (mouse) ______MsFFNFRKI S2-p
SLK (rat) ______MsFFNFRKI S2-p
S14-p
RKIFKLGsEKKKKQy
Upstream
0 7
Treatment
  • ischemia
SLK (human) RKIFKLGsEKKKKQy S14-p
SLK iso2 (human) RKIFKLGSEKKKKQY S14
SLK (mouse) RKIFKLGsEKKKKQY S14-p
SLK (rat) RKIFKLGsEKKKKQY S14-p
Y21-p
sEKKKKQyEHVKRDL
0 1
SLK (human) sEKKKKQyEHVKRDL Y21-p
SLK iso2 (human) SEKKKKQYEHVKRDL Y21
SLK (mouse) sEKKKKQYEHVKRDL Y21
SLK (rat) sEKKKKQYEHVKRDL Y21
T56-p
YKAQNKEtsVLAAAK
0 1
SLK (human) YKAQNKEtsVLAAAK T56-p
SLK iso2 (human) YKAQNKETSVLAAAK T56
SLK (mouse) YKAQNKETNVLAAAK T56
SLK (rat) YKAQNKETNVLAAAK T56
S57-p
KAQNKEtsVLAAAKV
0 2
SLK (human) KAQNKEtsVLAAAKV S57-p
SLK iso2 (human) KAQNKETSVLAAAKV S57
SLK (mouse) KAQNKETNVLAAAKV N57
SLK (rat) KAQNKETNVLAAAKV N57
T139-p
IQVVCKQtLDALNYL
0 1
SLK (human) IQVVCKQtLDALNYL T139-p
SLK iso2 (human) IQVVCKQTLDALNYL T139
SLK (mouse) IQVVCKQTLEALNYL T139
SLK (rat) IQVVCKQTLEALNYL T139
S177-p
KLADFGVsAkNtRtI
0 1
SLK (human) KLADFGVsAkNtRtI S177-p
SLK iso2 (human) KLADFGVSAKNTRTI S177
SLK (mouse) KLADFGVSAKNtRtI S177
SLK (rat) KLADFGVSAKNtRtI S177
K179-ub
ADFGVsAkNtRtIQR
0 1
SLK (human) ADFGVsAkNtRtIQR K179-ub
SLK iso2 (human) ADFGVSAKNTRTIQR K179
SLK (mouse) ADFGVSAKNtRtIQR K179
SLK (rat) ADFGVSAKNtRtIQR K179
T181-p
FGVsAkNtRtIQRRD
0 6
SLK (human) FGVsAkNtRtIQRRD T181-p
SLK iso2 (human) FGVSAKNTRTIQRRD T181
SLK (mouse) FGVSAKNtRtIQRRD T181-p
SLK (rat) FGVSAKNtRtIQRRD T181-p
T183-p
VsAkNtRtIQRRDsF
Upstream
Downstream
2 39
Effects on Modified Protein
  • enzymatic activity, induced
  • phosphorylation
Effects on Biological Processes:
  • apoptosis, induced
Putative in vivo kinases:
  • SLK (human)
Treatment
  • AP20187
  • erlotinib
SLK (human) VsAkNtRtIQRRDsF T183-p
SLK iso2 (human) VSAKNTRTIQRRDSF T183
SLK (mouse) VSAKNtRtIQRRDsF T183-p
SLK (rat) VSAKNtRtIQRRDsF T183-p
S189-p
RtIQRRDsFIGtPyW
Upstream
Downstream
2 342
Effects on Modified Protein
  • enzymatic activity, induced
  • phosphorylation
Effects on Biological Processes:
  • apoptosis, induced
Putative in vivo kinases:
  • PKACA (human)
  • SLK (human)
Treatment
  • AP20187
  • cAMP_analog
  • EGF
  • IBMX
  • NKH_477
SLK (human) RtIQRRDsFIGtPyW S189-p
SLK iso2 (human) RTIQRRDSFIGTPYW S189
SLK (mouse) RtIQRRDsFIGtPyW S189-p
SLK (rat) RtIQRRDsFIGTPYW S189-p
T193-p
RRDsFIGtPyWMAPE
Downstream
1 63
Effects on Modified Protein
  • enzymatic activity, induced
SLK (human) RRDsFIGtPyWMAPE T193-p
SLK iso2 (human) RRDSFIGTPYWMAPE T193
SLK (mouse) RRDsFIGtPyWMAPE T193-p
SLK (rat) RRDsFIGTPYWMAPE T193
Y195-p
DsFIGtPyWMAPEVV
0 13
SLK (human) DsFIGtPyWMAPEVV Y195-p
SLK iso2 (human) DSFIGTPYWMAPEVV Y195
SLK (mouse) DsFIGtPyWMAPEVV Y195-p
SLK (rat) DsFIGTPYWMAPEVV Y195
T206-p
PEVVMCEtSKDRPyD
0 4
SLK (human) PEVVMCEtSKDRPyD T206-p
SLK iso2 (human) PEVVMCETSKDRPYD T206
SLK (mouse) PEVVMCETSKDRPYD T206
SLK (rat) PEVVMCETSKDRPYD T206
Y212-p
EtSKDRPyDyKADVW
0 1
SLK (human) EtSKDRPyDyKADVW Y212-p
SLK iso2 (human) ETSKDRPYDYKADVW Y212
SLK (mouse) ETSKDRPYDYKADVW Y212
SLK (rat) ETSKDRPYDYKADVW Y212
Y214-p
SKDRPyDyKADVWSL
0 1
SLK (human) SKDRPyDyKADVWSL Y214-p
SLK iso2 (human) SKDRPYDYKADVWSL Y214
SLK (mouse) SKDRPYDYKADVWSL Y214
SLK (rat) SKDRPYDYKADVWSL Y214
S250-p
VLLKIAKsEPPTLAQ
0 1
SLK (human) VLLKIAKsEPPTLAQ S250-p
SLK iso2 (human) VLLKIAKSEPPTLAQ S250
SLK (mouse) VLLKIAKSEPPTLAQ S250
SLK (rat) VLLKIAKSEPPTLAQ S250
K298
FVTVDSNKPIRELIA
0 1
SLK (human) FVTVDSNKPIRELIA K298
SLK iso2 (human) FVTVDSNKPIRELIA K298
SLK (mouse) FVTVDSNkPVRELIA K298-ub
SLK (rat) FVTVDSNKPVRELIA K298
T327-p
EEDEEEEtENsLPIP
0 1
SLK (human) EEDEEEEtENsLPIP T327-p
SLK iso2 (human) EEDEEEETENSLPIP T327
SLK (mouse) EEDEEEEAENALPIP A327
SLK (rat) EEDDDDETESALPIP T327
S330-p
EEEEtENsLPIPAsK
Upstream
0 5
Treatment
  • BI2536
  • MLN8054
  • nocodazole
  • thymidine
SLK (human) EEEEtENsLPIPAsK S330-p
SLK iso2 (human) EEEETENSLPIPASK S330
SLK (mouse) EEEEAENALPIPANK A330
SLK (rat) DDDETESALPIPANK A330
S336-p
NsLPIPAsKRAssDL
0 3
SLK (human) NsLPIPAsKRAssDL S336-p
SLK iso2 (human) NSLPIPASKRASSDL S336
SLK (mouse) NALPIPANKRAssDL N336
SLK (rat) SALPIPANKRAsSDL N336
S340-p
IPAsKRAssDLsIAs
Upstream
0 20
Treatment
  • angiotensin_2
  • LPA
  • SII_angiotensin_2
SLK (human) IPAsKRAssDLsIAs S340-p
SLK iso2 (human) IPASKRASSDLSIAS S340
SLK (mouse) IPANKRAssDLsIAs S340-p
SLK (rat) IPANKRAsSDLSIAs S340-p
S341-p
PAsKRAssDLsIAss
0 8
SLK (human) PAsKRAssDLsIAss S341-p
SLK iso2 (human) PASKRASSDLSIASS S341
SLK (mouse) PANKRAssDLsIAss S341-p
SLK (rat) PANKRAsSDLSIAss S341
S344-p
KRAssDLsIAssEED
Upstream
0 11
Treatment
  • angiotensin_2
  • nocodazole
  • thymidine
SLK (human) KRAssDLsIAssEED S344-p
SLK iso2 (human) KRASSDLSIASSEED S344
SLK (mouse) KRAssDLsIAssEED S344-p
SLK (rat) KRAsSDLSIAssEED S344
S347-p
ssDLsIAssEEDKLs
Upstream
Downstream
1 32
Effects on Modified Protein
  • enzymatic activity, inhibited
Kinase, in vitro:
  • CK2A1 (rat)
Treatment
  • angiotensin_2
  • SII_angiotensin_2
SLK (human) ssDLsIAssEEDKLs S347-p
SLK iso2 (human) SSDLSIASSEEDKLS S347
SLK (mouse) ssDLsIAssEEDKLs S347-p
SLK (rat) sSDLSIAssEEDKLS S347-p
S348-p
sDLsIAssEEDKLsQ
Upstream
Downstream
1 30
Effects on Modified Protein
  • enzymatic activity, inhibited
Kinase, in vitro:
  • CK2A1 (rat)
Treatment
  • angiotensin_2
  • SII_angiotensin_2
SLK (human) sDLsIAssEEDKLsQ S348-p
SLK iso2 (human) SDLSIASSEEDKLSQ S348
SLK (mouse) sDLsIAssEEDKLsQ S348-p
SLK (rat) SDLSIAssEEDKLSQ S348-p
S354-p
ssEEDKLsQNACILE
0 16
SLK (human) ssEEDKLsQNACILE S354-p
SLK iso2 (human) SSEEDKLSQNACILE S354
SLK (mouse) ssEEDKLsQNACILE S354-p
SLK (rat) ssEEDKLSQNACILE S354
S362-p
QNACILEsVSEKTER
0 1
SLK (human) QNACILEsVSEKTER S362-p
SLK iso2 (human) QNACILESVSEKTER S362
SLK (mouse) QNACILESVSERTEQ S362
SLK (rat) QNACILESVSERTEH S362
S370-p
VSEKTERsNsEDKLN
0 2
SLK (human) VSEKTERsNsEDKLN S370-p
SLK iso2 (human) VSEKTERSNSEDKLN S370
SLK (mouse) VSERTEQSTSEDKFs S370
SLK (rat) VSERTEHNTSGDKFS N370
S372-p
EKTERsNsEDKLNSK
0 5
SLK (human) EKTERsNsEDKLNSK S372-p
SLK iso2 (human) EKTERSNSEDKLNSK S372
SLK (mouse) ERTEQSTSEDKFsNK S372
SLK (rat) ERTEHNTSGDKFSNK S372
N377
sNsEDKLNSKILNEK
0 1
SLK (human) sNsEDKLNSKILNEK N377
SLK iso2 (human) SNSEDKLNSKILNEK N377
SLK (mouse) STSEDKFsNKILNEK S377-p
SLK (rat) NTSGDKFSNKVLSEK S377
R415-m1
AMTELHDrTAVIKEN
0 1
SLK (human) AMTELHDrTAVIKEN R415-m1
SLK iso2 (human) AMTELHDRTAVIKEN R415
SLK (mouse) TGAELNDQTVGIHEN Q412
SLK (rat) TVAEPNDQAVGFHEN Q414
S446-p
QETVDINsVsEGKEN
0 2
SLK (human) QETVDINsVsEGKEN S446-p
SLK iso2 (human) QETVDINSVSEGKEN S446
SLK (mouse) QQTVDVNSVSEENEN S444
SLK (rat) QQTVDVNLVGEGNDS L446
S448-p
TVDINsVsEGKENNI
0 1
SLK (human) TVDINsVsEGKENNI S448-p
SLK iso2 (human) TVDINSVSEGKENNI S448
SLK (mouse) TVDVNSVSEENENNR S446
SLK (rat) TVDVNLVGEGNDSNI G448
T494-p
KSEEIKDtILQTVDL
0 1
SLK (human) KSEEIKDtILQTVDL T494-p
SLK iso2 (human) KSEEIKDTILQTVDL T494
SLK (mouse) QSEEINDTHIQTMDL T490
SLK (rat) QSEEIKDIHIQTMDL I492
T506-p
VDLVSQEtGEKEANI
0 1
SLK (human) VDLVSQEtGEKEANI T506-p
SLK iso2 (human) VDLVSQETGEKEANI T506
SLK (mouse) MDLVSQETGEKEADF T502
SLK (rat) MDLVSQETGEKEADF T504
S518-p
ANIQAVDsEVGLTKE
0 5
SLK (human) ANIQAVDsEVGLTKE S518-p
SLK iso2 (human) ANIQAVDSEVGLTKE S518
SLK (mouse) ADFQAVDNEVGLTKE N514
SLK (rat) ADFQAIDNEVGFTKE N516
S543
KTQKDVISNtsDVIG
0 1
SLK (human) KTQKDVISNtsDVIG S543
SLK iso2 (human) KTQKDVISNTSDVIG S543
SLK (mouse) TAQKVITsDRSsEVG S539-p
SLK (rat) KTHKVVISDITSEVG S541
T545-p
QKDVISNtsDVIGtC
0 1
SLK (human) QKDVISNtsDVIGtC T545-p
SLK iso2 (human) QKDVISNTSDVIGTC T545
SLK (mouse) QKVITsDRSsEVGTD R541
SLK (rat) HKVVISDITSEVGTD I543
S546-p
KDVISNtsDVIGtCE
Upstream
0 3
Treatment
  • nocodazole
  • thymidine
SLK (human) KDVISNtsDVIGtCE S546-p
SLK iso2 (human) KDVISNTSDVIGTCE S546
SLK (mouse) KVITsDRSsEVGTDE S542
SLK (rat) KVVISDITSEVGTDE T544
D547
DVISNtsDVIGtCEA
0 9
SLK (human) DVISNtsDVIGtCEA D547
SLK iso2 (human) DVISNTSDVIGTCEA D547
SLK (mouse) VITsDRSsEVGTDEA S543-p
SLK (rat) VVISDITSEVGTDEP S545
T551-p
NtsDVIGtCEAADVA
0 1
SLK (human) NtsDVIGtCEAADVA T551-p
SLK iso2 (human) NTSDVIGTCEAADVA T551
SLK (mouse) DRSsEVGTDEALDDt T547
SLK (rat) DITSEVGTDEPPGDT T549
A558
tCEAADVAQKVDEDs
0 1
SLK (human) tCEAADVAQKVDEDs A558
SLK iso2 (human) TCEAADVAQKVDEDS A558
SLK (mouse) TDEALDDtQKAAELS T554-p
SLK (rat) TDEPPGDTQKSAEQS T556
S565-p
AQKVDEDsAEDtQsN
0 17
SLK (human) AQKVDEDsAEDtQsN S565-p
SLK iso2 (human) AQKVDEDSAEDTQSN S565
SLK (mouse) tQKAAELSKAAQSGE S561
SLK (rat) TQKSAEQSQDAEGGA S563
T569-p
DEDsAEDtQsNDGKE
0 13
SLK (human) DEDsAEDtQsNDGKE T569-p
SLK iso2 (human) DEDSAEDTQSNDGKE T569
SLK (mouse) AAELSKAAQSGEGDE A564
SLK (rat) SAEQSQDAEGGAGEE A566
S571-p
DsAEDtQsNDGKEVV
0 25
SLK (human) DsAEDtQsNDGKEVV S571-p
SLK iso2 (human) DSAEDTQSNDGKEVV S571
SLK (mouse) ELSKAAQSGEGDEAL S566
SLK (rat) EQSQDAEGGAGEEAP G568
T643
TTEGEEITESsSTEE
0 12
SLK (human) TTEGEEITESsSTEE T643
SLK iso2 (human) TTEGEEITESSSTEE T643
SLK (mouse) TDEVEQVsEsNsIEE S643-p
SLK (rat) TDEVDQVsEsNsIEE S645-p
S645
EGEEITESsSTEEME
0 2
SLK (human) EGEEITESsSTEEME S645
SLK iso2 (human) EGEEITESSSTEEME S645
SLK (mouse) EVEQVsEsNsIEELE S645-p
SLK (rat) EVDQVsEsNsIEELE S647-p
S646-p
GEEITESsSTEEMEV
0 1
SLK (human) GEEITESsSTEEMEV S646-p
SLK iso2 (human) GEEITESSSTEEMEV S646
SLK (mouse) VEQVsEsNsIEELER N646
SLK (rat) VDQVsEsNsIEELER N648
S647
EEITESsSTEEMEVR
0 12
SLK (human) EEITESsSTEEMEVR S647
SLK iso2 (human) EEITESSSTEEMEVR S647
SLK (mouse) EQVsEsNsIEELERL S647-p
SLK (rat) DQVsEsNsIEELERL S649-p
S655-p
TEEMEVRsVVADTDQ
Upstream
0 6
Treatment
  • MG132_withdrawal
  • nocodazole
  • thymidine
SLK (human) TEEMEVRsVVADTDQ S655-p
SLK iso2 (human) TEEMEVRSVVADTDQ S655
SLK (mouse) sIEELERLVVTGAEA L654
SLK (rat) sIEELERLGVTGAEE L656
S667-p
TDQKALGsEVQDASK
0 9
SLK (human) TDQKALGsEVQDASK S667-p
SLK iso2 (human) TDQKALGSEVQDASK S667
SLK (mouse) AEARALGsEGEAAAT S666-p
SLK (rat) AEEQALGSKGEAATE S668
S728-p
ENKEEIGsLsKTETI
Upstream
0 3
Treatment
  • MG132_withdrawal
SLK (human) ENKEEIGsLsKTETI S728-p
SLK iso2 (human) ENKEEIGSLSKTETI S728
SLK (mouse) ENKEEMGALPKPETI A726
SLK (rat) ENKGEMGALPKPETI A727
S730-p
KEEIGsLsKTETILP
Upstream
0 1
Treatment
  • MG132_withdrawal
SLK (human) KEEIGsLsKTETILP S730-p
SLK iso2 (human) KEEIGSLSKTETILP S730
SLK (mouse) KEEMGALPKPETILP P728
SLK (rat) KGEMGALPKPETILP P729
T755-p
NDSGTGStADTSSID
0 1
SLK (human) NDSGTGStADTSSID T755-p
SLK iso2 (human) NDSGTGSTADTSSID T755
SLK (mouse) TDSGTGSTVENSSGD T753
SLK (rat) TDSGTGSTVENSSSD T754
S772-p
LSISSFLsKtkDsGs
0 1
SLK (human) LSISSFLsKtkDsGs S772-p
SLK iso2 (human) LSISSFLSKTKDSGS S772
SLK (mouse) LSISSFLSKAKDsGs S770
SLK (rat) LSISSFLSKTKDSGs S771
T774-p
ISSFLsKtkDsGsIs
0 1
SLK (human) ISSFLsKtkDsGsIs T774-p
SLK iso2 (human) ISSFLSKTKDSGSIS T774
SLK (mouse) ISSFLSKAKDsGsVs A772
SLK (rat) ISSFLSKTKDSGsVS T773
K775-m1
SSFLsKtkDsGsIsL
0 1
SLK (human) SSFLsKtkDsGsIsL K775-m1
SLK iso2 (human) SSFLSKTKDSGSISL K775
SLK (mouse) SSFLSKAKDsGsVsL K773
SLK (rat) SSFLSKTKDSGsVSL K774
S777-p
FLsKtkDsGsIsLQE
Upstream
0 11
Treatment
  • nocodazole
  • thymidine
SLK (human) FLsKtkDsGsIsLQE S777-p
SLK iso2 (human) FLSKTKDSGSISLQE S777
SLK (mouse) FLSKAKDsGsVsLQE S775-p
SLK (rat) FLSKTKDSGsVSLQE S776
S779-p
sKtkDsGsIsLQEtR
Upstream
0 39
Treatment
  • anti-CD3
  • EGF
  • MG132_withdrawal
  • nocodazole
  • thymidine
SLK (human) sKtkDsGsIsLQEtR S779-p
SLK iso2 (human) SKTKDSGSISLQETR S779
SLK (mouse) SKAKDsGsVsLQETR S777-p
SLK (rat) SKTKDSGsVSLQETR S778-p
S781-p
tkDsGsIsLQEtRRQ
0 8
SLK (human) tkDsGsIsLQEtRRQ S781-p
SLK iso2 (human) TKDSGSISLQETRRQ S781
SLK (mouse) AKDsGsVsLQETRRQ S779-p
SLK (rat) TKDSGsVSLQETRRQ S780
T785-p
GsIsLQEtRRQKKTL
0 8
SLK (human) GsIsLQEtRRQKKTL T785-p
SLK iso2 (human) GSISLQETRRQKKTL T785
SLK (mouse) GsVsLQETRRQKKTL T783
SLK (rat) GsVSLQETRRQKKTL T784
T814-p
VTTSKIVtDsDsKtE
0 32
SLK (human) VTTSKIVtDsDsKtE T814-p
SLK iso2 (human) VTTSKIVTDSDSKTE T814
SLK (mouse) VTTSKIVtDsDsKTE T812-p
SLK (rat) VTTSKIVTDSDSKTE T813
S816-p
TSKIVtDsDsKtEEL
0 21
SLK (human) TSKIVtDsDsKtEEL S816-p
SLK iso2 (human) TSKIVTDSDSKTEEL S816
SLK (mouse) TSKIVtDsDsKTEEL S814-p
SLK (rat) TSKIVTDSDSKTEEL S815
S818-p
KIVtDsDsKtEELRF
0 13
SLK (human) KIVtDsDsKtEELRF S818-p
SLK iso2 (human) KIVTDSDSKTEELRF S818
SLK (mouse) KIVtDsDsKTEELRF S816-p
SLK (rat) KIVTDSDSKTEELRF S817
T820-p
VtDsDsKtEELRFLR
0 4
SLK (human) VtDsDsKtEELRFLR T820-p
SLK iso2 (human) VTDSDSKTEELRFLR T820
SLK (mouse) VtDsDsKTEELRFLR T818
SLK (rat) VTDSDSKTEELRFLR T819
S850-p
RAQQQLNsKLQQQRE
0 1
SLK (human) RAQQQLNsKLQQQRE S850-p
SLK iso2 (human) RAQQQLNSKLQQQRE S850
SLK (mouse) RAQQQLNGKLQQQRE G848
SLK (rat) KAQQQLNGKLQQQRE G849
K917
EQEKELSKFQNMLKN
0 1
SLK (human) EQEKELSKFQNMLKN K917
SLK iso2 (human) EQEKELSKFQNMLKN K917
SLK (mouse) EQEKELSKFQNVLKN K915
SLK (rat) EQEKELSkFQNMLRN K916-ac
K1028
QLLKQQLKDQYFMQR
0 1
SLK (human) QLLKQQLKDQYFMQR K1028
SLK iso2 (human) QLLKQQLKDQYFMQR K997
SLK (mouse) QLLKQQLKDQYFMQR K1026
SLK (rat) QLLKQQLkDQYFIQR K996-ac
Y1052-p
ETEQMQRyNQRLIEE
0 1
SLK (human) ETEQMQRyNQRLIEE Y1052-p
SLK iso2 (human) ETEQMQRYNQRLIEE Y1021
SLK (mouse) ETEQMQRYNQRLIEE Y1050
SLK (rat) ETEQMQRYNQRLIEE Y1020
K1087
KTRMAMFKKsLRINs
0 1
SLK (human) KTRMAMFKKsLRINs K1087
SLK iso2 (human) KTRMAMFKKSLRINS K1056
SLK (mouse) KTRMAMFkkSLRINS K1085-ac
SLK (rat) KTRMAMFKKSLRINS K1055
K1088
TRMAMFKKsLRINsT
0 2
SLK (human) TRMAMFKKsLRINsT K1088
SLK iso2 (human) TRMAMFKKSLRINST K1057
SLK (mouse) TRMAMFkkSLRINST K1086-ac
SLK (rat) TRMAMFKKSLRINST K1056
S1089-p
RMAMFKKsLRINsTA
0 6
SLK (human) RMAMFKKsLRINsTA S1089-p
SLK iso2 (human) RMAMFKKSLRINSTA S1058
SLK (mouse) RMAMFkkSLRINSTA S1087
SLK (rat) RMAMFKKSLRINSTA S1057
S1094-p
KKsLRINsTAtPDQD
0 2
SLK (human) KKsLRINsTAtPDQD S1094-p
SLK iso2 (human) KKSLRINSTATPDQD S1063
SLK (mouse) kkSLRINSTATPDQD S1092
SLK (rat) KKSLRINSTATPDQD S1062
T1097-p
LRINsTAtPDQDRDK
Upstream
0 6
Treatment
  • MG132_withdrawal
  • nocodazole
  • thymidine
SLK (human) LRINsTAtPDQDRDK T1097-p
SLK iso2 (human) LRINSTATPDQDRDK T1066
SLK (mouse) LRINSTATPDQDREK T1095
SLK (rat) LRINSTATPDQDREK T1065
K1106
DQDRDKIKQFAAQEE
0 1
SLK (human) DQDRDKIKQFAAQEE K1106
SLK iso2 (human) DQDRDKIKQFAAQEE K1075
SLK (mouse) DQDREKIkQFAAQEE K1104-ub
SLK (rat) DQDREKIKQFAAQEE K1074
K1187
EKLRPRKKtLEEEFA
0 1
SLK (human) EKLRPRKKtLEEEFA K1187
SLK iso2 (human) EKLRPRKKTLEEEFA K1156
SLK (mouse) EKLRPRKktLEEEFA K1185-ub
SLK (rat) EKLRPRKKTLEEEFA K1155
T1188-p
KLRPRKKtLEEEFAR
0 4
SLK (human) KLRPRKKtLEEEFAR T1188-p
SLK iso2 (human) KLRPRKKTLEEEFAR T1157
SLK (mouse) KLRPRKktLEEEFAR T1186-p
SLK (rat) KLRPRKKTLEEEFAR T1156
K1205-m1
QEQEVFFkMTGESEC
0 1
SLK (human) QEQEVFFkMTGESEC K1205-m1
SLK iso2 (human) QEQEVFFKMTGESEC K1174
SLK (mouse) QEQEVFFKMTGESEC K1203
SLK (rat) QEQEVFFKMTGESEC K1173
S1219-p
CLNPSTQsRISKFyP
0 1
SLK (human) CLNPSTQsRISKFyP S1219-p
SLK iso2 (human) CLNPSTQSRISKFYP S1188
SLK (mouse) CLNPSAQSRISKFYP S1217
SLK (rat) CLNPSAQSRGCLQTS S1187
Y1225-p
QsRISKFyPIPsLHS
0 59
SLK (human) QsRISKFyPIPsLHS Y1225-p
SLK iso2 (human) QSRISKFYPIPSLHS Y1194
SLK (mouse) QSRISKFYPIPTLHs Y1223
SLK (rat) RGCLQTSHPSSTRAP H1195
S1229-p
SKFyPIPsLHSTGs_
0 3
SLK (human) SKFyPIPsLHSTGs_ S1229-p
SLK iso2 (human) SKFYPIPSLHSTGS_ S1198
SLK (mouse) SKFYPIPTLHsTGs_ T1227
SLK (rat) QTSHPSSTRAPAWAG T1199
S1232
yPIPsLHSTGs____
0 1
SLK (human) yPIPsLHSTGs____ S1232
SLK iso2 (human) YPIPSLHSTGS____ S1201
SLK (mouse) YPIPTLHsTGs____ S1230-gl
SLK (rat) gap -
S1235-p
PsLHSTGs_______
Upstream
0 6
Treatment
  • MG132_withdrawal
SLK (human) PsLHSTGs_______ S1235-p
SLK iso2 (human) PSLHSTGS_______ S1204
SLK (mouse) PTLHsTGs_______ S1233-p
SLK (rat) gap -